Group 1 - The law firm Shanghai Jiucheng has successfully filed a lawsuit for investor claims against Yingfeituo (002528), with the Shenzhen Intermediate People's Court accepting the case [1] - Investors who purchased Yingfeituo stock between April 30, 2020, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024, are eligible to initiate claims [2] - The China Securities Regulatory Commission (CSRC) has initiated a case against Yingfeituo for suspected violations of information disclosure laws [1] Group 2 - The law firm has also achieved a favorable ruling in a claim case for Ningke Biological (600165), with some investors already receiving compensation [2] - Ningke Biological's 2022 annual report was found to contain false records, inflating revenue by 76.5941 million and profit by 77.2220 million, which accounted for 11.25% and 46.59% of total revenue and profit, respectively [2] - Investors who bought Ningke Biological stock between November 22, 2022, and April 6, 2023, or between April 28, 2024, and October 31, 2024, are also eligible to file claims [3]

Core Viewpoint - The news highlights ongoing legal actions regarding investor claims against Yingfeituo and Ningke Biological, with recent court rulings favoring investors in both cases, indicating potential for further claims and compensation opportunities for affected shareholders [1][2][4]. Group 1: Yingfeituo (002528) - The Shenzhen Intermediate People's Court has accepted a case for investor claims against Yingfeituo, with previous rulings resulting in a win for investors [1][4]. - Investors who purchased Yingfeituo shares between April 30, 2020, and April 30, 2024, and sold or held shares after April 30, 2024, are eligible to initiate claims [2][5]. - The company received a notice from the China Securities Regulatory Commission (CSRC) on January 24, 2025, regarding an investigation into information disclosure violations [4]. Group 2: Ningke Biological (600165) - Ningke Biological has faced legal actions due to false reporting in its 2022 annual report, which overstated revenue by 76.59 million and profit by 77.22 million, representing 11.25% and 46.59% of total revenue and profit, respectively [2][5]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and a halt in key subsidiary operations [5][6]. - Investors who bought Ningke Biological shares between November 22, 2022, and April 6, 2023, or between April 28, 2024, and October 31, 2024, are also eligible to file claims [3][6].

Core Viewpoint - The news highlights ongoing legal actions against companies Yingfeituo and Zhongqingbao, with investors seeking compensation due to alleged violations of information disclosure laws and false financial reporting [1][2][3]. Group 1: Yingfeituo (002528) - Yingfeituo's investor compensation case has been submitted to the Shenzhen Intermediate People's Court, with some investors already winning in the first instance [1][7]. - The company received a notice from the China Securities Regulatory Commission (CSRC) on January 24, 2025, regarding an investigation into information disclosure violations [1][7]. - Investors who purchased Yingfeituo shares between April 30, 2020, and April 30, 2024, and sold or held them after April 30, 2024, are eligible to file for compensation [7]. Group 2: Zhongqingbao (300052) - Zhongqingbao's investor compensation case has also been submitted to the Shenzhen Intermediate People's Court, with ongoing acceptance of new claims from investors [2][3]. - The company was found to have false records in its annual reports from 2019 to 2021, involving fictitious transactions that inflated revenue and profits [3][4]. - Specific financial manipulations included an inflated revenue of 33.61 million yuan in 2019 (7.17% of reported revenue), 28.09 million yuan in 2020 (9.56%), and 17.88 million yuan in 2021 (5.03%) [4][9]. - Investors who bought Zhongqingbao shares between March 27, 2020, and April 27, 2023, or between April 23, 2024, and July 29, 2024, are also eligible for compensation claims [5][10].

Core Viewpoint - Shenzhen Investment Holdings Co., Ltd. has reported significant debt issues, with a total of 57.5 million yuan in early maturing loans and overdue debts amounting to 320.6 million yuan, raising concerns about its financial stability and potential impacts on operations [1] Debt Situation - As of February 10, 2026, the total early maturing debt principal from Infitop Bank loans is 57.5 million yuan, which constitutes 32.78% of the audited net assets for 2024 [1] - The cumulative overdue principal debt for Infitop and its subsidiaries is 320.6 million yuan, representing 182.78% of the company's audited net assets for 2024 [1] - The overdue interest amounts to 1.21498 million yuan [1] Guarantees and Communication - Infitop has provided joint liability guarantees for its subsidiaries, covering overdue amounts of 43.89707 million yuan [1] - The company is actively communicating with creditors to find solutions and has stated that these issues are not expected to have a significant adverse impact on the parent company's production operations, financial status, or debt repayment capabilities [1]

Core Viewpoint - The article discusses the ongoing legal proceedings involving Infitop (002528) and the investor compensation claims being handled by attorney Xu Feng from Shanghai Jiucheng Law Firm, highlighting the company's legal challenges and the potential for investor compensation [1] Group 1: Legal Proceedings - Xu Feng, representing investors in the Infitop compensation case, has submitted a new case to the Shenzhen Intermediate People's Court [1] - Some parts of the investor compensation case have already received a favorable first-instance judgment, with Infitop appealing and entering the second-instance phase [1] - The law firm continues to accept compensation claims from other investors [1] Group 2: Regulatory Actions - On January 24, 2025, Infitop announced it received a "Notice of Case Filing" from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The CSRC's decision to file a case against the company is based on the Securities Law and the Administrative Penalty Law [1] Group 3: Investor Eligibility for Claims - Investors who purchased Infitop stock between April 30, 2020, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024, are eligible to initiate compensation claims [1]

Core Viewpoint - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, is actively pursuing investor compensation cases against Yingfeituo (002528) due to alleged violations of information disclosure laws, with ongoing legal proceedings and a recent court ruling in favor of investors [1][2][3]. Group 1: Legal Proceedings - On February 10, 2026, Shanghai Jiucheng submitted another case for compensation on behalf of Yingfeituo investors to the Shenzhen Intermediate People's Court [1]. - Some cases have already received a favorable first-instance judgment for investors, while Yingfeituo has appealed, entering the second-instance phase [1][2]. - The legal team is continuing to accept new compensation claims from other investors [1][2]. Group 2: Regulatory Actions - On January 24, 2025, Yingfeituo announced that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [3]. - The CSRC's decision to investigate is based on the Securities Law and the Administrative Penalty Law [3]. Group 3: Investor Compensation Eligibility - According to lawyer Xu Feng, investors who purchased Yingfeituo stock between April 30, 2020, and April 30, 2024, and sold or continued to hold the stock after April 30, 2024, are eligible to initiate compensation claims [2][3].

Group 1 - The company received a notice from Huaxia Bank Shenzhen Branch regarding the early maturity of part of its debts, with a total principal amount of 57,500,000.00 yuan, accounting for 32.78% of the company's audited net assets for 2024 [1][2] - As of the date of the announcement, the total overdue debt (including early maturity) amounts to 320,615,277.38 yuan, which is 182.78% of the company's audited net assets for 2024 [3] - The overdue interest not paid is 1,214,975.62 yuan, representing 0.30% of the absolute value of the net profit attributable to shareholders of the listed company for 2024 [3] Group 2 - The company and its subsidiaries provided joint liability guarantees for bank loans taken by subsidiaries, with overdue amounts totaling 43,897,068.50 yuan, including principal of 42,910,901.02 yuan and interest of 986,167.48 yuan [3] - Due to overdue debts and early maturity, the company may incur additional financial costs such as penalties and interest, which could lead to increased financial expenses and reduced financing capabilities [4] - The company is actively communicating with creditors to explore feasible solutions to address the overdue debt issues [4]

深圳英飞拓科技股份有限公司 关于公司部分债务提前到期的公告 证券代码：002528 证券简称：ST 英飞拓 公告编号：2026-007 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要提示： 近日，深圳英飞拓科技股份有限公司（以下简称"英飞拓"或"公司"）收 到华夏银行股份有限公司深圳分行（以下简称"华夏银行深圳分行"）《提前到期 通知书》，公司新增提前到期债务本金合计 57,500,000.00 元，占公司 2024 年经 审计净资产的比例为 32.78%。截至本公告披露日，累计债务逾期（含提前到期） 本金合计 320,615,277.38 元，占公司 2024 年经审计净资产的比例为 182.78%；逾 期未付的利息 1,214,975.62 元，占公司 2024 年经审计归属于上市公司股东的净 利润绝对值的比例为 0.30%。债务逾期（含提前到期）本金及逾期未付利息合计 321,830,253.00 元。 敬请广大投资者谨慎投资，注意投资风险。 一、本次部分银行贷款提前到期的情况 2026 年 1 月 27 日，公司在《证券时报》《证券日报》《中国证 ...

Core Viewpoint - The news discusses ongoing legal actions regarding investor claims against companies Yingfeituo (002528) and Xiangrikui (300111) due to alleged violations of information disclosure laws, with both cases currently in various stages of litigation [1][2][3][4][5]. Group 1: Yingfeituo (002528) - The law firm represented by attorney Xu Feng has submitted a new case for investor claims against Yingfeituo to the Shenzhen Intermediate People's Court on February 3, 2026 [1][4]. - A previous ruling in favor of investors has been made, with Yingfeituo appealing the decision, which has now entered the second trial phase [1][4]. - The company received a notice from the China Securities Regulatory Commission (CSRC) on January 24, 2025, regarding an investigation into alleged information disclosure violations [4]. Group 2: Xiangrikui (300111) - On February 3, 2026, attorney Xu Feng also submitted a new case for investor claims against Xiangrikui to the Shaoxing Intermediate People's Court, which is awaiting further court arrangements [2][4]. - The company received a notice from the CSRC on January 14, 2026, regarding an investigation into misleading statements related to its restructuring proposal [3][5]. - Investors who purchased Xiangrikui shares between September 22, 2025, and December 26, 2025, and sold or held them after December 26, 2025, are eligible to file claims [5].

深圳市投资控股有限公司公告，公司下属子公司英飞拓及其全资子公司英飞拓仁用、英飞拓智能、英飞 拓软件和英飞拓智园发生部分债务逾期，英飞拓为全资子公司向银行借款提供连带责任保证担保，英飞 拓担保逾期。截至2026年1月27日，英飞拓债务逾期本金及逾期未付利息合计8514.27万元。另外，英飞 拓为子公司向银行借款提供连带责任保证担保，英飞拓担保逾期，逾期金额4412.03万元。英飞拓正积 极与债权机构沟通，探讨切实可行的解决方案。 ...